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Abstract: Stenotrophomonas maltophilia (S. maltophilia) is its best known species because it is a globally 
emerging, multidrug-resistant (MDR), opportunistic pathogen. The aim of the study was to identify species in this 
collection, defined as genetically cohesive sequence clusters, and to determine the extent of their genetic, ecological 
and phenotypic differentiation. This framework was used to analyze 50 specimens for cultures were collected from 
patients in the military hospital in Hanoi, Vietnam, between 2015 and 2017. Three of the 30 MDR S. maltophilia 
isolates identified by Vitek technology in hospital were confirmed using 16S rRNA gene sequencing. The alignment 
sequences were analyzed in RAxML version 8.2.10 to estimate the best maximum likelihood phylogenetic tree, with 
1,000 bootstrap replicates, estimated GTRGAMMA model and the rapid bootstrapping algorithm. Over 70% of S. 
maltophilia isolates were resistant to β-lactams (such as carbapenem, penicilline, monobactam, amoxicillin, cephem, 
and β-lactam); Aminoglycosides (such as gentamycine and tobramycin); Miscellaneous (such as fosfomycin and 
chloramphenicol). In particularly, all of this strain isolates were resistant to β-lactams and Aminoglycosides high 
annual increasing/ frequency from 2015 to 2017 year. Three resistant strains with most antibiotics (S. maltophilia 
17-87M, 17-95M and 17-90N) were randomly selected to test the association between genotype and phenotypic 
resistance. The results were shown a significantly different in antibiotic genes expression among three strains and a 
few difference in phenotypic resistance. These data in light of current models of bacterial speciation, which fit these 
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 Stenotrophomonas maltophilia is widely distributed in the environment, and is found commonly 
in soil, water, plants, and animals [1]. Currently, S. maltophilia is reported to be a special opportunistic 
pathogen in the hospital, increasing the frequency of bacteria isolation, and especially the life-threatening 
infection of patients [2, 3]. Mortality rates of S. maltophilia patients ranged from 14% to 69% [1]. 
Although S. maltophilia is a bacterium that is not present high virulent, it can be transmitted between 
hospitalized patients with depression, immunodeficiency, and especially in patients with severe infections 
and neuropathy [1]. A survey in 2012 reported that S. maltophilia is one of the four leading pathogens 
related to intra-abdominal infections in Asia [4]. Also in 2012, another program (as SENTRY 
Antimicrobial Surveillance program) indicated that S. maltophilia is one of ten pathogens that cause 
pneumonia in patients at Latin American medical centers [5]. In addition, more and more cases of S. 
maltophilia have been reported in the community [6]. A 11-year statistic of the Canadian care institute 
also found that the bacteria were present in 45.8% of patients with multicellular infections [7].  
 In particular, the severity of S. maltophilia multi-antibiotic resistance has increased throughout 
the world in recent years [3, 5]. In many cases, the treatment of S. maltophilia infection is very difficult 
because of the high level of resistance to many antibiotic groups [5, 8]. ]. In Taiwan, a case of S. 
maltophilia infection isolated in special care units could resist to many type of antimicrobial drugs 
recommended for clinical use [9]. [10] was isolated a S. maltophilia strain in China that could resist most 
antibiotics and higher than any other S. maltophilia strains. In Japan, this bacterium is also a serious 
problem because of its increasing frequency of antibiotic resistance in the clinical environment [11]. A 
report in 2017 by Egupt indicated that S. maltophilia is an emerging pathogen at Assiut University 
Hospital with high resistance to many antimicrobial drugs [12]. S. maltophilia has a high intrinsic 
resistance to a number of antibiotics. The multidrug resistant abilities of S. maltophilia have demonstrated 
in a broad spectrums of antibiotics, including β-lactams, minoglycosides, quinolones, aminoglycosides, 
tetracycline, disinfectants, and heavy metals [13, 14]. MDR S.maltophilia enabled via several of 
molecular mechanisms including reduced permeability of the outer membrane, efflux pumps, 
chromosomally and plasmids, transposons, integrons and biofilms [1, 15, 16]. It is noteworthy that S. 
maltophilia can also obtain resistance through the uptake of resistance genes located integrons, 
transposons, and plasmids or via horizontal gene transfer and mutations from the natural environment. 
Therefore, infection diseases caused by clinical S. maltophilia isolates are particularly difficult to manage 
because they show resistance to many antimicrobial drugs, creating a challenge in treatment and finding 
appropriate antibiotics [1]. It is important to identify antibiotic resistance genotypes and phenotypes of S. 
maltophilia isolated under hospital infection control conditions [17]. A large amount of data on the 
complete genome sequence of S. maltophilia has allowed the alignment and annotation of total 
antimicrobial resistance genes. However, the role of these resistant genes in coding inactivated enzymes 
and multi efflux pumps, also as in intrinsic resistance mechanisms is limited and requires further study. 
We aimed to investigate the antibiotic resistance of S. maltophilia, identify MDR S. maltophilia strains 
through 16S rRNA gene sequence, and examine the expression of antibiotic genes predicted from the S. 
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maltophilia genome sequence. In addition, we also evaluated the correlation between genotype and 
phenotype of MDR S. maltophilia strains isolated in a military hospital. 
Materials and Methods 
Clinical specimens and identification of Stenotrophomonas maltophilia strains 
 Clinical specimens for bacterial culture were collected from patients at a military hospital in 
Hanoi, Vietnam during 2015-2017. The species were initially identified using the Vitek 2 GN ID card and 
antimicrobial susceptibility tested using the Vitek 2 Antimicrobial Susceptibility Tests (bioMérieux, 
Mercy l’Etoile, France). The isolates identified as Stenotrophomonas maltophilia strains were enriched on 
LB broth for using molecular methods and stored frozen in this medium supplemented with 20% (V/V) 
glycerol at -800C. 
Genomic DNA isolation, PCR amplification of 16S rRNA sequences and their phylogenetic analysis 
 Total DNA samples were extracted according to the GeneJET Genomic DNA Purification Kit 
(Thermo Fisher Scienctific, USA) guidelines. The 16S rRNA gene was amplified by Polymerase Chain 
Reaction (PCR) using the universal primers as Table 1. PCR was carried out using PCR Veriti® 96-Well 
Thermal Cycler (Applied Biosystems, USA) and conditions as reported previously [18]. PCR products 
were purified with GenJet PCR Purification kit (Thermo Fisher Scientific, USA) and sequenced directly 
using a protocol for “Taq Cycle Sequencing” and fluorescent dye-labeled dieoxynucleotide by the ABI 
3500 Genetic Analyzer (Thermo Fisher Scientific, USA).  
 The 16S rRNA gene sequences data of three MDR S. maltophilia strains (as S.maltophilia 
17-87M,  17-90N, and 17-95M) were aligned with reference DNA sequences using evolutionarily 
conserved primary sequence and secondary structure as reference to reconstruct the phylogenetic trees. 
Sequence alignments were conducted with the ClustalW program (www.ebi.ac.uk/clustalw). The 
clustering of these MDR S. maltophilia strains were supported by high bootstrap values, and placed 
within the genus S. maltophilia clade in the phylogenetic trees that reconstructed with the 
maximum-likelihood method using RAxML version 8.2.10 with General Time Reversible-GAMMA. 
Finally, Fig. Tree v1.4.2 software was used to read exported format file for the phylogenetic tree 
construction. The sequences generated in this study for 16S rRNA gene sequence analysis were deposited 
in GenBank/NCBI under accession numbers MK156781, MK156783, and MK158159 for S. maltophilia 
17-87M, 17-90N, and 17-95M, respectively. 
RNA extraction and determination of antibiotic resistance gene expression profiles 
 Total RNA extraction and cDNA synthesis were performed following the guidelines of 
GeneJET RNA Purification Kit and RevertAid First Strand cDNA Synthesis Kit (Thermo Fisher 
Scientific, USA), respectively. Three antibiotic resistant gene groups [e.g., L2- β-lactam gene (β-lactam), 
aac6 and aph3 genes (Aminoglycosides), and smeD and QacE genes (Quinolones)] were tested in RNA 
samples of the randomly MDR S. maltophilia strains (e.g., S. maltophilia 17-87M, 17-95M and 17-90N) 
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via RT- PCR in order to test the association between genotype and phenotypic antibiotic resistance. The 
primers used in RT- PCR analysis are described in Table 1. Samples were analyzed in a 20 μl reaction 
volume containing 1 μl of complementary DNA template, 2 μl of 10X buffer, 2 μl of dNTP mix, 0.5 μl of 
5 pmol of each primer, and 0.2 μl of 5U of Taq DNA polymerase (Bangalore Genei, Bangalore, India). 
Cycling kinetics were performed using 20, 25, and 30 cycles, to ensure linearity of PCR product detection. 
Finaly, a volume of 8 μl of PCR product was loaded on 2% agarose gel and stained with ethidium 
bromide. The gel photograph was scanned and analyzed using Quantity One program (Gel Doc EQ; 
Bio-Rad, Hercules, CA). The relative expression level of each gene was normalized to that of 16S rRNA 
(i.e., an internal control gene) and quantified using RQ software (Applied Biosystems). 
Statistical Analyses 
 The results were analyzed using commercially available software GraphPad Prism5 for 
Windows Edition (GraphPad Software Inc., La Jolla, CA). The significant changes of gene expression 
between strains were detected by one-way ANOVA, Tukey’s multiple regression test was used to 
compare the gene expression (i.e., by comparing among strains). A p values were 2-tailed and a p value 
<0.05 was considered statistically significant. 
Results  
Identified S. maltophilia from patients during three years  
 As in other countries, this bacterium is problematic in Vietnam and the frequency of its isolation 
in clinical settings is increasing. From 2015 to 2017, 50 patients were identified S.maltophilia in the 
clinical microbiologic laboratory of a hospital. The rate of detecting patients infected with this bacterium 
has increased, only 12 cases (24%) were detected in 2015, then increased to 20 cases (40%) and 18 cases 
(36%) in 2016 and 2017, respectively. All most of blood cultures grew S. maltophilia (35/ 50, about 
70 %). The clinical characteristics of the patients are summarized in Table 2. Among the 50 patients, 38 
(76%) were male and 12 (24%) were female, and the mean age was 61.08 ± 18.68 years. The high ratios 
of patients were from internal medicine and surgery medicine (54% and 46%, respectively). Thirty 
percent of patients had an identifiable source of nosocomial bacteremia, among which the chronic 
pulmonary disease (30%) and emergency (20%) were the most common. 
16S rRNA gene sequence analyses and relationships of S. maltophilia strains isolated from 
Vietnamese patients and other strains 
 The 16S rRNA gene sequences data from three random MDR S. maltophilia strains (namely 
17-87M; 17-90N, and 17-95M) were completed, by cluster analysis, and reference sequence data analysis 
in order to confirm the isolated strains which had been observed previously from disk/ or Vitek data. In 
the Fig. 1 was presented the estimated phylogenetic positions of species of the genus S.maltophilia. 
Comparative 16S rRNA gene sequence analysis showed that three MDR Stenotrophomonas strains 
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isolated from Vietnamese patients represented a member of the genus Stenotrophomonas (class 
Gammaproteobacteria). S. maltophilia was related most closely to S. maltophilia strain ATCC19861 
(bootstrap 82), followed by S. pavanii strain ICB89 (bootstrap 98). The bootstrap values to other type 
strains of species of the genus Stenotrophomonas were upper 70. While S. maltophilia clearly was seen to 
branch outside the cluster formed by the Pseudomonas aeruginosa species. This observation suggests a 
potential for the use of 16S rRNA gene sequence data in diagnostic analyses of Stenotrophomonas 
phytopathogens. Others studies showed that PCR amplification targeting a region of the 16S rRNA gene 




Figure 1 Phylogenetic analysis based on 16S rRNA gene sequences obtained from the three MDR S. maltophilia 
isolates in this study and fifteen sequences retrieved from GenBank database (Pseudomonas aeruginosa was 
included as outgroup). Phylogenetic tree was created by RAxML version 8.2.10. 
 
 The similarity values determined from pairwise comparisons among 16R rRNA gene sequencing 
of S. maltophilia isolated from Vietnamese patients and other S. maltophilia species listed in Table 3. The 
nucleotide sequences of the 16S rRNA gene in three S. maltophilia strains (17-87M, 17-90N, and 17-95M) 
out of 50 isolates had high identity with other clinically significant S. maltophilia. The amino acid 
sequence displayed most identity with standard S. maltophilia ATCC19861 variants (98.2; 98.1, and 
98.5%, respectively), and pairwise sequence similarities to other strains of Stenotrophomonas were upper 
93 %. Thus, in all subsequent analyses, three Vietnamese S. maltophilia strains was considered to be a 
member of the S. maltophilia species. The sequence data have been deposited with the GenBank/ NCBI 
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database under accession numbers as MK156781, MK156783, and MK158159 of S. maltophilia 17-87M, 
S. maltophilia 17-90N, and S. maltophilia 17-95M, respectively. 
Antimicrobial resistance of the clinical isolates of S. maltophilia  
 The antimicrobial resistance of 50 isolates of S. maltophilia was performed in Table 4. All of 
these isolates were resistant to β-lactams, aminoglycosides, quinolones, tetracycline, and miscellaneous. 
Based on the antibiotics that were tested on over 30 tests showed that the most active agents were 
carbapenem (92.16%, 47/51 tested), penicillin (90.91%, 30/33 tested), cephem (83.91%, 73/87 tested), 
and β-lactam (74.47%, 35/47 tested). Among the antibiotics tested, fluoroquinolone was the highest 
effective against 54.72% (29/53 tested) of the isolates. Most of the isolates (56.0 %) were resistant to 
multiple antibiotics (more of the three drugs tested), and one isolate were resistant to sixteen antibiotics 
tested.  
 There was a tendency to increase resistance to the agents used to treat S. maltophilia during the 
study period (Fig. 2). The results were most pronounced with antibiotics of β-lactam, aminoglysosides, 




Figure 2 The year to year changes in resistance and susceptibility rates of Stenotrophomonas maltophilia to 
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Figure 3 (A-E) Gel electrophoresis of the PCR 
amplified products of aac (6')-Iz (A), aph (3')-IIc 
(B), L2-β lactam (C), QacE (D), and smeD (E) 
genes of S. maltophilia isolates. The sequence of 
forward and revered primers, Tm, and size of PCR 
amplified products were performed in Table 1. The 
study analyzed expression databased on the 
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Antibiotic resistant genes expression in the opportunistic pathogen S.maltophilia  
 Recent research shows that S. maltophilia has a low sensitivity to many antibiotics, including 
antibiotics commonly used to treat infections caused by it. Analysis of resistance mechanisms and 
identification of antibiotic resistance genes may help in finding specific antibiotics for treatment of S. 
maltophilia. When using bioinformatics tools to predict genes that show a high homology with known 
antibiotic resistance genes, however, their exact function is still confirmed [16]. In this study, we 
analyzed the expression profiles of five different antibiotic resistance genes (e.g., smeD, L2-β lactam, aph 
(3')-IIc, aac (6')-Iz, and QacE genes), which represent antibiotic resistant phenotypes such as 
chloramphenicol, tetracycline, quinolones, beta-lactams, aminoglycosides, and multidrug efflux. The 
results indicated that most of the genes associated with resistance in S. maltophilia have been found 
present in all strains examined (Fig. 3 A-E). 
 In the S. maltophilia 17-87M strain, the expression of four genes (e.g., L2-β lactam, aac (6')-Iz, 
QacE, and smeD genes) was very high level and showed a significant fold differences in gene expression 
analysis compared to these genes expression in other strains (p < 0.01).  Particularly for two isolates as S. 
maltophilia 17-90N and 17-95M strains, the level of expression of antibiotic resistance genes were varies. 
For example, in S. maltophilia 17-90N strain showed a significant difference in down expression of both 
aac (6')-Iz and L2-β lactam genes compared to the other two strains (p < 0.05). Meanwhile, the expression 
level of three genes (e.g., aph (3')-IIc, QacE, and smeD genes) in S. maltophilia 17-95M strain, were 
shown a significant for fold differences in low expression compared than the two strains S. maltophilia 
17-87M and 17-90N. Although, all three MDR S. maltophilia strains were resistant phenotype to 
β-lactams, aminoglycosides, quinolones, and miscellaneous, the level of expression of antibiotic resistant 
genes was different between strains, thus there is a little similarity between genotype and phenotype 
expression. The mechanism of the gene that determines the antibiotic resistance abilities of S. maltophilia 
bacteria should be further studied. 
Discussion 
 Similar to other studies, our bacteria were also mainly found in blood samples. Most male 
patients were infected this bacterium with the main symptom was respiratory infection. This may due to S. 
maltophilia often causes a variety of infections including respiratory tract and blood stream infections [15, 
21]. A similar study of [22] was reported that 65.2% of S. maltophilia isolated from blood. [23] reported 
that 23.7% of all community acquired blood stream infections were caused by S. maltophilia. Another 
study on the prevalence of S. maltophilia in Taiwan also revealed that 17.6% of all acquired blood 
infections in the community were due to S. maltophilia [2]. [24] also indicated that the respiratory tract 
was the most common source of S. maltophilia bacteremia (33%) and male gender (75%).   
 Recently, clinical epidemiological studies have shown a genetic diversity of S. maltophilia 
strains, probably the result of natural selection by antibiotic pressure [25]. In particular, the emergence of 
MDR S. maltophilia strains has led to the difficult treatment of S. maltophilia infection. In clinical 
treatment of S. maltophilia, only 39% of patients were treated with appropriate antibiotics, because the 
bacteria were resistant to most antibiotics including carbapenems [26]. In the study of [27] about 66 S. 
maltophilia strains isolated from a university hospital in Japan were resistant to imipenem (100 %), 
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aztreonam (98.5 %), tetracycline (97.0 %), piperacillin (93.9 %), amikacin (87.9 %), ciprofloxacin 
(84.8 %), ceftazidime (84.8 %), gentamicin (81.8 %), and chloramphenicol (78.8 %). The SMX/TMP 
resistance rates have been reported up to 50%, in which the lower resistance level as in the Western 
Hemisphere range between 2 - 10%, Spain: 27%, Turkey: 10 - 15%, Taiwan: up to 25%, and China 30 - 
48% [14, 28]. In addition, S. maltophilia can resistant to a number of other antibiotics, most notably 
aminoglycosides and most of the β-lactam antibiotics due to various resistance mechanisms [1, 14, 29]. In 
this study, the clinical isolated S. maltophilia strains were resistant to many antibiotic groups, such as 
β-lactam, aminoglysosides, tetracycline, and miscellaneous. Total 56.0% of which were multi-resistant 
strains with carbapenem, penicillin, cephem, and β-lactam, although these are antibiotics used for the 
treatment of S. maltophilia infection currently. Therefore, the management of S. maltophilia infections in 
our hospital may be quite difficult. The reason that is predicted due to indiscriminate and uncontrolled use 
of antibiotics in Vietnamese patients has created a number of S. maltophilia strains expressing high-level 
intrinsic resistance to a broad spectrum of antibiotics. 
 Some recent studies were found a series genes related to the β-lactamases antibiotic resistance in 
S.maltophilia from Egypt [12, 30], Greece and South Korea [31, 32], Iran [33] and Germany [34]. S. 
maltophilia expects to be resistant to β-lactam antibiotics, because it carries the L1 and L2 β-lactamase 
genes on the chromosome [35, 36]. The expression of both β-lactamases is controlled via the function of 
the master regulator AmpR in the presence of β-lactam antibiotics [12]. The data presented in this study 
showed the expression of L2 β-lactamase gene in all MDR S. maltophilia strains, however there was a 
difference between genotype and phenotypic resistance of β-lactamases among strains. Indeed, a weak 
expression of the L2 β-lactamase gene was present in one strain (17-90N), whereas a strong expression in 
two other strains, thus the role of L1 and L2- β-lactamase genes in the main mechanism responsible for 
intrinsic resistance to β -lactams of S. maltophilia should be studied further. There are a large number of 
antibiotic inactivating enzymes and efflux pumps in S.maltophilia [2, 35]. In particular, SmeDEF is 
involved in both intrinsic and acquired resistance to chloramphenicol, tetracycline, quinolones, and 
non-antibiotic compounds [37]. Many previous studies were indicated that S. maltophilia quinolone 
resistance is due to overexpression of efflux pumps [8, 38], and the presence of class1 integrons 
associated with low susceptibility in clinical strains [9, 39]. In the study, three MDR S. maltophilia strains 
also showed a low susceptibility to synthetic antibiotics such as quinolones. However, the antibiotic 
resistance mechanisms operating in clinical S. maltophilia strains are limited information in this report. S. 
maltophilia have low susceptibility to aminoglycoside antibiotics due to contain aph (3′) -IIc and 
aac(6′)-Iz genes that encode two alter aminoglycoside enzymes. In which, aph (3′) -IIc gene encodes 
anaminoglycoside phosphotransferase [40], while aac(6′)-Iz gene codes foran N-aminoglycoside 
acetyltransferase [41]. Gene aac(6′)-Iz was identified in 57% of the aminoglycoside resistance S. 
maltophilia isolates [42]. Another previous study also indicated that some isolates produced an 
aminoglycoside acetyltransferase or presented an aph gene in the S. maltophilia genome has reduced 
susceptibility to aminoglycoside antibiotics [41].  [40] reported that the newly aph(3)-II gene in S. 
maltophilia encoding a protein that regulates the mechanism of resistance to aminoglycoside agents, and a 
homologue of aph(3)-IIc gene in all the isolates tested, thus this gene may be an intrinsic resistance gene 
in S. maltophilia. In our study, the significant different in aac(6′)-Iz gene with respect to the 
aminoglycoside resistance of clinical S. maltophilia strains was indicated. These results reported that 
aac(6′)-Iz gene was an important contributor to aminoglycoside resistance in clinical strains of S. 
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maltophilia, however, more studies are needed to confirm their function. Moreover, another result have 
been shown in three MDR S. maltophilia isolates in which all of these strains expressed aph(3)-IIc gene, 
in particular, the S. maltophilia 17-90N was 1.2 fold up aph(3)-IIc gene expression compare two other 
strains and it also performed a strong aminoglycoside resistant phenotype in tested. The Qac genes are 
often noticed when combined with genes that encode resistance to β-lactams, aminoglycosides, 
trimethoprim-sulphonamides, and chloramphenicol [43, 44]. This study showed that the high expression 
of qacE gene in MDR S.maltophilia 17-87M strain was similar to the antibiotic resistant phenotype of this 
strain. It has been suggested that an increase in antibiotic resistance in this bacterium is related to the 
presence of qacE gene. In addition, the expression of qacE gene in MDR S.maltophilia 17-87M strain 
was higher than two other strains as MDR S.maltophilia 17-90N and 17-95M. The increased frequency of 
antibiotic resistance genes in clinical S.maltophilia specimens indicates that the hospital environment can 
selectively pressure the presence of these strains and contribute to survival of MDR strains.  
Conclusions 
 In conclusion, our results have shown the high prevalence of S. maltophilia isolated in the 
hospital environment, especially more than 50% of the isolated strains could be resistant to most of 
antimicrobial agents recommended for clinical use. The study results also indicated a similarity between 
the genotype and phenotype of antibiotic resistant in the clinical S.maltophilia strains. From the aspect of 
this study, it is necessary to implement strict control measures in the hospital environment to prevent the 
infection of S.maltophilia bacteria, especially to continuously monitor to avoid source of spread of 
resistance genes. In addition, additional modern tests are needed to provide information on acquired 
resistance-related genes. Because the early identification of antibiotic resistance phenotype makes identify 
appropriate antibiotics for treatment, improve survival rates, and control the source of this bacterial 
outbreak in the hospital. 
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Table 1 Oligonucleotide primers used in this study 
 
Primer Sequencing (5’-3’) Size/ Tm Product/  
antibiotic resistance phenotype 
smeD Forward CCAAGAGCCTTTCCGTCAT 150 bp; 
58oC 




     
L2-β lactam Forward CGTCGCCGATTCCTGCAGTT 410 bp; 
58oC 
Beta-lactamase/  
Beta-lactams Reverse CGGTGTTGTCGCTGGTGATG 
     
aph (3')-IIc Forward ATGGAAGCACCCAATCC 660 bp; 
50oC 
Aminoglycoside phosphotransferase/ 
Aminoglycosides Reverse TGCTGGCGTGGGACAACA 
     
aac (6')-Iz Forward CGTGAACGGTACCGAGTCTT 233 bp; 
50oC 
N-Aminoglycoside acetytransferase/  
Aminoglycosides Reverse GCATGCGGAAATAGACGAC 
     
QacE Forward GAAGGCTTCACCAAGCTCAC 126 bp; 
50oC 




     
16S rRNA Forward CCTACGGGAGGCAGCAG 550 bp; 
50oC 
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Table 2 Clinical characteristics of 50 patients with S. maltophilia bacteria 
 
Characteristics No (%) 
Age [mean ± SD (years)] 61.08 ± 18.68 
Gender  
          Male 38 (76 %) 
          Female 12 (24 %) 
Department  
Internal medicine 27 (54 %) 
Surgery medicine 23 (46 %) 
Underlying disease  
Hypertension  4 (8 %) 
Diabetes mellitus  3 (6 %) 
Emergency 10 (20%) 
Surgical Rheumatology  7 (14 %) 
Sepsis/ bacteremia 3 (6 %) 
Chronic pulmonary disease  15 (30 %) 
Gastrointestinal hemorrhage 2 (4 %) 
Chronic liver disease  5 (10 %) 
Renal insufficiency  1 (2 %) 
Congestive heart failure  1 (2 %) 
Source of infection  
Blood 35 (70 %) 
Wound swab 4 (8 %) 
Pus 2 (4 %) 
Pleural 1 (2 %) 
Bronchial 2 (4 %) 
Sputum 2 (4 %) 
Tracheal secretions 1 (2 %) 
Urine 2 (4 %) 
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Table 3 Similarity values determined from pairwise comparisons among 16R rRNA gene sequencing of S. maltophilia isolated from Vietnamese patients and 











































1 S. pavanii strain ICB 89  FJ748683.2  ID                 
2 S. maltophilia ATCC 19861 AB021406.1  97.9 ID                
3 S.chelatiphaga strain LPM-5 EU573216.1  96.7 95.6 ID               
4 S. tumulicola T5916-2-1b LC066089.1  97.5 96.4 98.1 ID              
5 S. panacihumi strain MK06 GQ856217.1  96.4 95.0 95.6 96.5 ID             
6  S. rhizophila strain e-p10 AJ293463.1  96.9 95.6 96.6 97.5 97.7 ID            
7 S. bentonitica strain BII-R7 HG800055.1  97.7 96.2 96.9 97.5 96.5 98.1 ID           
8 S. ginsengisoli strain DCY01 DQ109037.1 96.0 96.0 95.8 96.9 95.0 95.6 96.4 ID          
9 S. koreensis AB166885.1  97.1 96.0 97.1 98.1 95.6 96.7 97.5 98.4 ID         
10 S. terrae strain R-32768T AM403589.2  95.8 94.3 95.1 96.0 95.8 96.5 96.9 96.4 97.5 ID        
11 S. nitritireducens strain L2 AJ012229.1  96.0 94.5 95.2 96.2 96.4 96.7 97.1 96.5 97.7 99 ID       
12 S. humi strain R-32729T AM403587.1  95.4 93.9 94.7 96.0 96.0 96.2 96.5 96.4 97.1 99.2 99.4 ID      
13 S. acidaminiphila  AF273080.1  96.2 94.7 95.4 96.4 95.8 96.5 97.3 96.7 97.9 99.2 99.4 98.8 ID     
14 S. daejeonensis strain MJ03  GQ241320.1   94.7 93.7 95.1 95.6 94.8 95.2 95.6 96.2 96.5 97.5 98.1 97.5 97.9 ID    
15 S. maltophilia Vietnam 17 -87M MK156781 99.2 98.2 96.6 97.3 95.8 96.4 97.1 95.4 96.9 95.2 95.4 94.8 95.6 94.1 ID   
16 S. maltophilia Vietnam 17 -90N MK156783 98.8 98.6 96.2 96.9 95.4 96.0 96.7 95.8 96.5 94.8 95.0 94.5 95.2 93.7 99.6 ID  
17 S.  maltophilia Vietnam 17 
-95M 
MK158159 99.2 98.2 96.6 97.3 95.8 96.4 97.1 95.4 96.9 95.2 95.4 94.8 95.6 94.1 100 99.6 ID 
  
 Ivy Union Publishing | http: //www.ivyunion.org   ISSN 2572-5815               January 22, 2019 | Volume 7 | Issue 1  
 





Table 4 Antimicrobial resistance values of S. maltophilia isolated from hospital during 2015 - 2017 
 










β-lactams    1) Vitek 
2) Vitek + 
E-TEST 
3) Vitek + Disk 
4) E-TEST 
5) Disk 
Penicillin (33) 30 (90.91) 3 (9.09)  
β-lactam (47) 35 (74.47) 12 (25.53)  
Amoxycillin (24) 20 (83.33) 4 (16.67)  
Monobactam (19) 17 (89.47) 2 (10.53)  
Cephem (87) 73 (83.91) 10 (11.49) 4 (4.60) 
Carbapenem (51) 47 (92.16) 4 (7.84)  
Ceftazidime (2) 1 (50.00)  1 (50.00) 
Aminoglycosides    
Kanamycin (3) 3 (100)   
Gentamicin (9) 8 (88.89) 1 (11.11)  
Tobramycin (6) 5 (83.33) 1 (16.67)  
Streptogramin (3) 1 (33.33) 2 (66.67)  
Quinolones     
Fluoroquinolone (53) 23 (43.40) 29 (54.72) 1 (1.89) 
Levofloxacin (2)  2 (100)  
Nitrofurantoin (1)  1 (100)  
Tetracycline     
Tetracycline (6) 1 (16.67) 5 (83.33)  
Minocycline (3) 1 (33.33) 1 (33.33) 1 (33.33) 
Doxycycline (3)  3 (100)  
Miscellaneous     
Fosfomycin (19) 17 (89.47) 2 (10.53)  
Folate pathway inhibitor (23) 2 (8.70) 21 (91.30)  
Glycylcycline (1)  1 (100)  
Trimethoprim-sulfamethoxazole (1)  1 (100)  
Lincosamid (3) 1 (33.33) 1 (33.33) 1 (33.33) 
Chloramphenicol (4) 3 (75.00) 1 (25.00)  
Nitrofurantoin (1) 1 (100)   
Linezolid (6) 2(33.33) 4 (66.67)  
 
